Abstract
Tumor behavior and outcome are believed to be modified by undifferentiated stromal fibroblasts that surround epithelial cells. An understanding of the biology of these fibroblasts could shed light on the mechanisms underlying tumor growth, invasion and progression, and may suggest new targets for therapy. In breast cancer, interactions between malignant breast epithelial cells and fibroblasts are responsible for estrogen biosynthesis. Preclinical studies showed that breast cancer epithelial cells secrete factors that enhance the expression and activity of the estrogen-synthesizing enzyme aromatase in undifferentiated adipose fibroblasts. Clinicopathological data showing an abundance of stroma cells in breast cancer, and the clinical finding that aromatase inhibitors are effective in breast cancer treatment indicate that stromal cells play a prominent role in the microenvironment of breast cancer tissue. The analysis of the stromal signature could provide information about the molecules involved in the epithelial-stromal interaction and reveal new potential treatment targets in distinct biological processes. This article focuses on breast cancer in terms of: 1) epithelial and stromal cell populations; 2) epithelial-stromal signaling and targeted therapies; and 3) stroma-related molecular signatures as a tool to identify potential candidate molecules for target therapy.
Keywords: Epithelial stromal mesenchymal interaction, breast cancer, target therapy.
Clinical Cancer Drugs
Title:The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment
Volume: 1
Author(s): Bianca Maria Veneziani, Micaela Montanari, Maria Letizia Cataldo, Luigi Coppola, Agostina Nardone, Sara Corvigno, Carmine De Angelis, Grazia Arpino, Mario Giuliano, Chiara Carlomagno, Roberto Bianco and Sabino De Placido
Affiliation:
Keywords: Epithelial stromal mesenchymal interaction, breast cancer, target therapy.
Abstract: Tumor behavior and outcome are believed to be modified by undifferentiated stromal fibroblasts that surround epithelial cells. An understanding of the biology of these fibroblasts could shed light on the mechanisms underlying tumor growth, invasion and progression, and may suggest new targets for therapy. In breast cancer, interactions between malignant breast epithelial cells and fibroblasts are responsible for estrogen biosynthesis. Preclinical studies showed that breast cancer epithelial cells secrete factors that enhance the expression and activity of the estrogen-synthesizing enzyme aromatase in undifferentiated adipose fibroblasts. Clinicopathological data showing an abundance of stroma cells in breast cancer, and the clinical finding that aromatase inhibitors are effective in breast cancer treatment indicate that stromal cells play a prominent role in the microenvironment of breast cancer tissue. The analysis of the stromal signature could provide information about the molecules involved in the epithelial-stromal interaction and reveal new potential treatment targets in distinct biological processes. This article focuses on breast cancer in terms of: 1) epithelial and stromal cell populations; 2) epithelial-stromal signaling and targeted therapies; and 3) stroma-related molecular signatures as a tool to identify potential candidate molecules for target therapy.
Export Options
About this article
Cite this article as:
Veneziani Maria Bianca, Montanari Micaela, Cataldo Letizia Maria, Coppola Luigi, Nardone Agostina, Corvigno Sara, Angelis De Carmine, Arpino Grazia, Giuliano Mario, Carlomagno Chiara, Bianco Roberto and Placido De Sabino, The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment, Clinical Cancer Drugs 2014; 1 (1) . https://dx.doi.org/10.2174/2212697X113016660008
DOI https://dx.doi.org/10.2174/2212697X113016660008 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Targeting to the Brain - A Review
Current Nanoscience Immunomodulatory Effects of <i>Allium sativum</i> L. and its Constituents against Viral Infections and Metabolic Diseases
Current Topics in Medicinal Chemistry Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents [10]-Gingerol Affects Multiple Metastatic Processes and Induces Apoptosis in MDAMB- 231 Breast Tumor Cells
Anti-Cancer Agents in Medicinal Chemistry Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability
Current Drug Delivery Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets An Overview of Current Applications of Nanotechnology in Biomedical Research: A Patent Survey
Recent Patents on Nanomedicine Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Protein & Peptide Letters ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Nutrition in Adult Patients with Inflammatory Bowel Disease
Current Drug Targets Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Meet Our Editorial Board Member
Letters in Drug Design & Discovery In Situ Intestinal Perfusion in Rodents: Future Perspectives for Application on Absorption Studies and Classification of Drugs
Mini-Reviews in Medicinal Chemistry